Market closedNon-fractional
Amgen/AMGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Ticker
AMGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Thousand Oaks, United States
Employees
26,700
Website
www.amgen.com
Amgen Metrics
BasicAdvanced
$179B
Market cap
47.71
P/E ratio
$7.01
EPS
0.60
Beta
$8.64
Dividend rate
2.58%
Dividend yield
Price and volume
Market cap
$179B
Beta
0.6
Dividend rate
$8.64
Financial strength
Current ratio
1.422
Quick ratio
0.836
Long term debt to equity
1,195.958
Total debt to equity
1,274.791
Dividend payout ratio (TTM)
122.96%
Interest coverage (TTM)
2.29%
Management effectiveness
Return on assets (TTM)
4.88%
Return on equity (TTM)
72.57%
Valuation
Price to earnings (TTM)
47.707
Price to revenue (TTM)
6.062
Price to book
35.71
Price to tangible book (TTM)
-3.99
Price to free cash flow (TTM)
25.221
Dividend yield (TTM)
2.58%
Growth
Revenue change (TTM)
12.76%
Earnings per share change (TTM)
-52.39%
3-year revenue growth (CAGR)
5.48%
3-year earnings per share growth (CAGR)
-16.58%
3-year dividend per share growth (CAGR)
9.62%
What the Analysts think about Amgen
Analyst Ratings
Majority rating from 31 analysts.
Amgen Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.4B
-9.14%
Net income
-$113M
-114.73%
Profit margin
-1.51%
-116.15%
Amgen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$5.00
$4.96
$4.71
$3.96
-
Expected
$4.49
$4.67
$4.61
$3.87
$4.97
Surprise
11.30%
6.16%
2.27%
2.32%
-
Amgen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amgen stock?
Amgen (AMGN) has a market cap of $179B as of July 27, 2024.
What is the P/E ratio for Amgen stock?
The price to earnings (P/E) ratio for Amgen (AMGN) stock is 47.71 as of July 27, 2024.
Does Amgen stock pay dividends?
Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of July 27, 2024, the dividend rate is $8.64 and the yield is 2.58%. Amgen has a payout ratio of 122.96% on a trailing twelve-month basis.
When is the next Amgen dividend payment date?
The next Amgen (AMGN) dividend payment date is unconfirmed.
What is the beta indicator for Amgen?
Amgen (AMGN) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Amgen stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.